Evidence map›Paper›PMID 31133982›Full record

ArticleFrontiers in endocrinology2019

Hypogonadism and Sexual Dysfunction in Testicular Tumor Survivors: A Systematic Review.

Sandro La Vignera, Rossella Cannarella, Ylenia Duca, Federica Barbagallo, Giovanni Burgio, Michele Compagnone, Andrea Di Cataldo, Aldo E Calogero, Rosita A Condorelli

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Testicular cancer survivorship: Long-term toxicity and management.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2022
    Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Sandro La VigneraSection of Endocrinology, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
Rossella CannarellaSection of Endocrinology, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
Ylenia DucaSection of Endocrinology, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
Federica BarbagalloSection of Endocrinology, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
Giovanni BurgioSection of Endocrinology, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
Michele CompagnoneSection of Endocrinology, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
Andrea Di CataldoUnit of Pediatric Hematology and Oncology, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
Aldo E CalogeroSection of Endocrinology, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
Rosita A CondorelliSection of Endocrinology, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Testicular tumor is the most common malignancy in men of reproductive age. According to the tumor histology and staging, current treatment options include orchiectomy alone or associated with adjuvant chemo- and/or radiotherapy. Although these treatments have considerably raised the percentage of survivors compared to the past, they have been identified as risk factors for testosterone deficiency and sexual dysfunction in this subgroup of men. Male hypogonadism, in turn, predisposes to the development of metabolic and cardiovascular impairment that negatively affects general health. Accordingly, longitudinal studies report a long-term risk for cardiovascular diseases after radiotherapy and/or cisplatin-based chemotherapy in testicular tumor survivors. The aim of this review was to summarize the current evidence on hypogonadism and sexual dysfunction in long-term cancer survivors, including the epidemiology of cardiovascular and metabolic disorders, to increase the awareness that serum testosterone levels, sexual function, and general health should be evaluated during the endocrinological management of these patients.

Indexed as

cardiovascular riskhypogonadismsexual dysfunctiontesticular tumortestosterone

Identifiers

PMID31133982
PMCPMC6513875

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.